Because GC patients with positive expression of YAP1 and HSPC111 were associated with a poorer prognosis than those that were negative for YAP1 and HSPC111, we propose that these factors comprise prognostic biomarkers for GC patient outcomes. This evidence concerns the gene NOP16 and gastric cancer.